Sirolimus protein-bound particles
Term · Oncology and biomedicine · MLC-T-ONC-007790
A form of the drug sirolimus that is used to treat adults with malignant perivascular epithelioid cell tumor that has spread or cannot be removed by surgery. It is also being studied in the treatment of other types of cancer. Sirolimus protein-bound particles may have fewer side effects and work better than other forms of sirolimus. It binds to a protein called mTOR, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Sirolimus protein-bound particles is a type of kinase inhibitor, a type of angiogenesis inhibitor, and a type of immunosuppressant. Also called Fyarro.
| Identifier | MLC-T-ONC-007790 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | Fyarro |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-007790",
"term": "Sirolimus protein-bound particles",
"field": "Oncology and biomedicine",
"definition": "A form of the drug sirolimus that is used to treat adults with malignant perivascular epithelioid cell tumor that has spread or cannot be removed by surgery. It is also being studied in the treatment of other types of cancer. Sirolimus protein-bound particles may have fewer side effects and work better than other forms of sirolimus. It binds to a protein called mTOR, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Sirolimus protein-bound particles is a type of kinase inhibitor, a type of angiogenesis inhibitor, and a type of immunosuppressant. Also called Fyarro.",
"synonyms": [
"Fyarro"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/sirolimus-protein-bound-particles/"
}
Record 15,030 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.